General Dermatology
Eczema
Alopecia
Aesthetics
Vitiligo
COVID-19
Actinic Keratosis
Precision Medicine and Biologics
Rare Disease
Wound Care
Rosacea
Psoriasis
Psoriatic Arthritis
Atopic Dermatitis
Melasma
NP and PA
Skin Cancer
Hidradenitis Suppurativa
Drug Watch
Pigmentary Disorders
Acne
Pediatric Dermatology
Practice Management
Prurigo Nodularis

Clinical Impact of Topical Ruxolitinib Cream: Physician Satisfaction & Treatment Patterns in Atopic Dermatitis : Episode 2

Real-World Clinical Experience With Ruxolitinib Cream Monotherapy to Manage Atopic Dermatitis

June 6, 2024

By Lawrence Eichenfield, MD

Opinion

Video

In this recently presented poster, a dermatology expert draws on clinical experience to reveal why healthcare providers switch treatments for atopic dermatitis (AD). The expert also examines how these reasons vary with disease stage and patient demographics, offering nuanced insights into AD management.

EP: 1.Insights for Clinicians: Leveraging Real-World Data for Informed Practice

Now Viewing

EP: 2.Real-World Clinical Experience With Ruxolitinib Cream Monotherapy to Manage Atopic Dermatitis

EP: 3.Treatment Transitions: Exploring Clinical Responses to Ruxolitinib Monotherapy for Atopic Dermatitis Management

EP: 4.Atopic Dermatitis Treatments Before and After Initiation of Ruxolitinib Cream: Analysis of a US Payer Claims Database

EP: 5.Mitigating Alternative Topical Treatments: Ruxolitinib's Role in Atopic Dermatitis Management

EP: 6.Exploring the Clinical Impact of Topical Ruxolitinib Cream in Atopic Dermatitis

In your experience, what are the most commonly cited reasons by healthcare providers for switching treatments in patients with AD?
In your experience, how might these factors vary across different stages of the disease or patient populations?
How do you interpret the implications of the majority of patients experiencing improved disease control upon transitioning to ruxolitinib cream, particularly concerning disease management strategies and patient outcomes?